MedTrace Logo

Effectivness of Topical Tacrolimus Monotherapy in Patients With Vitiligo

NCT03358082 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2017-11-30

No results posted yet for this study

Summary

The study will evaluate the effectiveness of Tacrolimus 0.03% ointment monotherapy in patients with vitiligo. Patients will be treated for 6 months and followed for 3 months after treatment. All types of vitiligo will be included.

Conditions

  • Vitiligo
  • Tacrolimus

Interventions

DRUG

Tacrolimus 0.03% Ointment

topical tacrolimus 0.03% twice daily for 6 months

DRUG

Hydrocortisone Acetate 1% Ointment

hydrocortisone acetate 1% ointment twice daily for 6 months

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Principal Investigators

  • Ramadan Saleh, MD · Sohag Faculty of Medicine, Sohag University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-01
Primary Completion
2018-12-01
Completion
2019-02-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03358082 on ClinicalTrials.gov